MINI FUTURE LONG - VERTEX PHARMACEUTICALS | Real-time Bid/Ask 05:43:07 27/06/2024 pm IST | ||
| 18.54 EUR / 18.85 EUR | +1.05% |
|
| Current month | +10.65% | ||
| 1 month | +9.86% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Latest news about VERTEX PHARMACEUTICALS INCORPORATED
More news
| Date | Price | Change |
|---|---|---|
| 27/24/27 | 18.47 | -0.16% |
| 26/24/26 | 18.5 | +0.93% |
| 25/24/25 | 18.33 | -1.56% |
| 24/24/24 | 18.62 | +2.42% |
| 21/24/21 | 18.18 | -0.38% |
Delayed Quote Börse Stuttgart
Last update June 27, 2024 at 04:08 pm IST
More quotesStatic data
| Product type | Certificat Turbo Stop Loss |
|---|---|
| Buy / Sell | CALL |
| Underlying | VERTEX PHARMACEUTICALS INCORPORATED |
| Issuer | Morgan Stanley |
| WKN | MD5HWD |
| ISIN | DE000MD5HWD2 |
| Date issued | 23/06/2022 |
| Strike | 276.5 $ |
| Maturity | Unlimited |
| Parity | 10 : 1 |
| Emission price | 3.81 € |
| Emission volume | N/A |
| Settlement | règlement en espèces |
| Currency | EUR |
Technical Indicators
| Highest since issue | 19.49 € |
|---|---|
| Lowest since issue | 3.8 € |
| Spread | 0.31 € |
| Spread % | 1.64% |
Company Profile
Vertex Pharmaceuticals Incorporated specializes in the research, development and marketing of micromolecular drugs primarily for the treatment of cancers, viral, inflammatory and auto-immune diseases.
Net sales are distributed geographically as follows: the United States (61.2%), Europe (31.5%) and other (7.3%).
Sector
-
Ratings for Vertex Pharmaceuticals Incorporated
Trading Rating
Investor Rating
ESG Refinitiv
B+
Consensus: Vertex Pharmaceuticals Incorporated
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
32
Last Close Price
474
USD
Average target price
468.3
USD
Spread / Average Target
-1.21%
- Stock Market
- Certificates
- Certificat
